# Marietta Wu

> Marietta Wu is a Series A investor at Quan Capital backing Pharmaceutical and Health Care. See 9 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Quan Capital](https://shizune.co/investors/profile/quan-capital)
- Total investments: 9
- Last investment: May 2024
- Lead investor: 33%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/marietta-wu-573231

Marietta Wu is a Series A investor at Quan Capital focused on Pharmaceutical and Health Care. Prior to joining Burrill, Dr. Wu held professional positions with Edwards Lifesciences and Eli Lilly & Company. She was Director of Strategy at Edwards, responsible for the strategic planning in the biologics program. At Eli Lilly & Company Oncology and Integrated Biology, Dr. Wu oversaw finance, business development, pipeline valuation,organizational restructure and outsourcing strategy. She also worked at Eli Lilly’s M&A Group and with Oncology Discovery Research. Dr. Wu founded BioHorizon, a consultancy focused on value creation in the life sciences industry across the Pacific Rim. She advised a number of biotech start-ups and venture capital firms.Dr. Wu’s scientific expertise centers on basic and clinical research in oncology and neuroscience. She was selected by Nobel Laureate Dr. Marshall Nirenberg as an IRTA Fellow at the National Institutes of Health (NIH). Dr. Wu received her M.D. from Shanghai Second Medical University, a Ph.D. in Medical Sciences from Medical College of Ohio, and an MBA from the University of Michigan Business School.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Pharmaceutical | 4 | 44% |
| Health Care | 3 | 33% |
| Biotechnology | 2 | 22% |
| Medical | 1 | 11% |
| Biopharma | 1 | 11% |

7 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 3 | 33% |
| Series B | 3 | 33% |
| Series C | 2 | 22% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| China | 2 | 22% |
| United States | 2 | 22% |
| United Kingdom | 1 | 11% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Zenas BioPharma | Zenas BioPharma is a biopharmaceutical company that focuses on developing immune-based therapies for patients. The company is headquartered in Florida, USA. | $200M | Series C | May 07, 2024 |  |
| Alebund Pharmaceuticals | Alebund Pharmaceuticals is a biopharmaceutical company dedicated to developing innovative therapies for the treatment of renal diseases and related chronic conditions. | $29.1M | Series C | Apr 12, 2023 |  |
| Zenas BioPharma | Zenas BioPharma is a biopharmaceutical company that focuses on developing immune-based therapies for patients. The company is headquartered in Florida, USA. | $118M | Series B | Nov 07, 2022 |  |
| Alebund Pharmaceuticals | Alebund Pharmaceuticals is a biopharmaceutical company dedicated to developing innovative therapies for the treatment of renal diseases and related chronic conditions. | $54.5M | Series B | Sep 13, 2021 |  |
| Alebund Pharmaceuticals | Alebund Pharmaceuticals is a biopharmaceutical company dedicated to developing innovative therapies for the treatment of renal diseases and related chronic conditions. | $60M | Series B | May 09, 2021 |  |
| Zenas BioPharma | Zenas BioPharma is a biopharmaceutical company that focuses on developing immune-based therapies for patients. The company is headquartered in Florida, USA. |  | Series A | Mar 23, 2021 |  |
| Citrine Medicine | Citrine Medicine is a rare disease-focused pharmaceutical firm. | $80M | Series A | Jul 13, 2020 |  |
| RareStone Group (Previously Citrine Medicine) | Citrine Medicine is a rare disease-focused pharmaceutical firm. | $80M | Series A | Jul 13, 2020 |  |
| Crescendo Biologics | Crescendo Biologics is a new Cambridge-based company whose vision is to deliver next-generation antibody therapeutics based on novel class-leading platforms.The focus of the company is on developing platforms that will address key issues in generating high-affinity, soluble, human VH antibody fragments. These are the smallest fragments thatretain antibody binding, and have many desirable properties as potential therapeutics. Crescendo will then utilise these platforms for product development of in-house targets or in partnership with other companies. | $70M | Series B | Apr 30, 2018 |  |

9 of 9 investments shown.

## Co-investors
- [3H Health Investment](https://shizune.co/investors/profile/3h-health-investment) — VC Fund, 4 deals together
- [Vivo Capital](https://shizune.co/investors/profile/vivo-capital) — VC Fund, 4 deals together
- [Fairmount Funds Management](https://shizune.co/investors/profile/fairmount-funds-management) — VC Fund, 3 deals together
- [Lilly Asia Ventures](https://shizune.co/investors/profile/lilly-asia-ventures) — VC Fund, 3 deals together
- [Wellington Management](https://shizune.co/investors/profile/wellington-management) — VC Fund, 3 deals together
- [3E Bioventures](https://shizune.co/investors/profile/3e-bioventures) — VC Fund, 2 deals together

## About Quan Capital

VC Fund · Shanghai, China

Quan Capital discover, incubate and grow next-generation life sciences companies. Their unique investment philosophy enables us to explore disruptive solutions to critical healthcare problems impacting the lives of millions. Their portfolio companies are pioneers in breakthrough therapies and cutting-edge technologies that will generate significantvalue to patients. In addition, they are investing in leading players that fulfill the rapid growing needs in a nascent innovation driven eco-system in China.

4 contacts available at Quan Capital.

| Name | Title | Profile |
| --- | --- | --- |
| Marietta Wu | Managing Director | https://shizune.co/investors/profile/marietta-wu |
| Peter Wirth | Venture Partner | https://shizune.co/investors/profile/peter-wirth |
| Samantha DU | Founder & Managing Director | https://shizune.co/investors/profile/dr-samantha-du |
| Stella Xu | Managing Director | https://shizune.co/investors/profile/stella-xu |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Marietta Wu invest in?

Marietta Wu invests primarily in Pharmaceutical, Health Care and Biotechnology startups, most often at Series A and Series B stage. Most of the 9 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Marietta Wu last invest?

The most recent investment recorded for Marietta Wu closed in May 2024. Shizune tracks 9 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co